Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


20/20 GeneSystems, Inc.

Latest From 20/20 GeneSystems, Inc.

New Products In Brief

Mela Sciences launches MelaFind melanoma detection device in the U.S. Medtronic launches CapSure Sense MRI SureScan pacing leads overseas. More product news.

Medical Device

Biomarker Diagnostics: Place Your Bets Wisely

Biomarker diagnostics are the linchpin of personalized medicine. But building a successful business around such tests is anything but straightforward, given the complexities associated with both their development and commercialization. Today's molecular diagnostic companies need to think carefully before they choose a "go it alone" strategy when developing a particular test. It may make more sense to forge a partnership with another diagnostic company or a drug developer with the goal of sharing costs and relative risks.

Medical Device Business Strategies

Clinical Update (10/2006)

Short summaries of notable clinical findings impacting the device industry: blood test may detect early-stage lung cancer; new device may help regrow teeth.

Medical Device Clinical Trials
See All

Company Information

  • Industry
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Digital Health
    • Artificial Intelligence
  • Other Names / Subsidiaries
    • 20/20 BioResponse